Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical leader developing oral peptide therapies for inflammatory and hematologic conditions. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely announcements about PTGX's innovative constrained peptide platform and pipeline candidates like icotrokinra (IL-23 antagonist) and rusfertide (hepcidin mimetic). Our curated collection includes press releases on trial results, FDA communications, and collaborations with industry leaders including Johnson & Johnson.
Key updates cover therapeutic advancements for psoriasis, ulcerative colitis, and polycythemia vera. Bookmark this page to monitor Protagonist's progress in transforming biologic-like treatments into oral formulations while maintaining competitive positioning through proprietary drug discovery methods.
Protagonist Therapeutics (PTGX) reported substantial progress in Q2 2021, achieving significant milestones in its clinical trials. Key updates include the completion of enrollment for its Phase 2 study of rusfertide in polycythemia vera, which received FDA Breakthrough Therapy Designation. Financially, the company raised approximately $132.2 million from a public offering. However, license revenues decreased to $2.3 million, and R&D expenses rose to $26.4 million. The net loss was $30.8 million, or $0.69 per share, compared to a previous loss of $19.4 million. Future milestones include Phase 3 studies set for early 2022.
Protagonist Therapeutics (Nasdaq: PTGX) announced an amended collaboration with Janssen Biotech for the development of oral Interleukin-23 receptor antagonists, including PTG-200, PN-232, and PN-235. The revised agreement potentially enables Protagonist to earn $900 million in future milestones, in addition to $80 million already received. Janssen assumes financial responsibility for future studies, reducing Protagonist's development obligations. This collaboration supports the advancement of innovative treatments for Crohn's disease and other indications.
On June 30, 2021, Protagonist Therapeutics (Nasdaq: PTGX) granted an inducement award to Patrick Smith, the new Vice President of Quality Assurance, as part of his employment agreement. The award includes an option to purchase 45,000 shares at an exercise price of $45.05, the stock’s closing price on that date. Shares will vest over four years, with 25% vesting after the first year. This award adheres to Nasdaq rules and aims to incentivize Mr. Smith's role within the company. Protagonist develops peptide-based therapeutics, including treatments for polycythemia vera and ulcerative colitis.
Protagonist Therapeutics (Nasdaq:PTGX) has successfully closed a public offering of 3,503,311 shares at $37.75 per share, raising approximately $132.2 million in gross proceeds. This includes 456,953 shares sold due to the underwriters' full exercise of their green shoe option. The offering's strategic execution involved J.P. Morgan, Jefferies, and Piper Sandler as joint book-running managers. The final prospectus has been filed with the SEC, and more details can be accessed via the agency's website.
Protagonist Therapeutics (PTGX) announced the pricing of its underwritten public offering of 3,046,358 shares at $37.75 each, totaling approximately $115 million in gross proceeds. The offering's closure is anticipated around June 18, 2021, subject to customary conditions. Underwriters have a 30-day option to purchase an additional 456,953 shares. J.P. Morgan, Jefferies, and Piper Sandler lead this offering. The shares are being offered under a shelf registration filed with the SEC on December 10, 2020, and the accompanying prospectus will be available through designated financial institutions.
Protagonist Therapeutics (PTGX) has announced a public offering of $100 million in shares of its common stock, with a 30-day option for underwriters to purchase an additional 15%. The offering is managed by J.P. Morgan, Jefferies, and Piper Sandler, alongside other firms as co-leads. The offering is subject to market conditions, and there are no guarantees regarding its completion. A related shelf registration statement has been filed with the SEC. This move is part of Protagonist's strategy to leverage funds for its clinical-stage biopharmaceutical operations.
Protagonist Therapeutics (PTGX) has announced updated results from its Phase 2 study of rusfertide for treating polycythemia vera (PV), presented at the EHA 2021 Virtual Congress. The study showed rusfertide effectively maintained hematocrit levels and reduced the need for therapeutic phlebotomies. Positive outcomes included improved patient-reported symptoms and reversal of iron deficiency. The drug's safety profile was favorable, and the company is preparing to advance into Phase 3 trials in early 2022 following FDA's Breakthrough Therapy Designation.
Protagonist Therapeutics (PTGX) announced a conference call on June 11, 2021, to discuss data from its ongoing Phase 2 study of rusfertide in treating polycythemia vera (PV). The study's results will be presented at the European Hematology Association 2021 Annual Congress. Notable participants include Ronald Hoffman, M.D., a key investigator in the trial. Protagonist aims to initiate a global Phase 3 trial based on feedback from regulatory authorities, focusing on efficacy and safety. The call will be accessible to investors and the public.
Protagonist Therapeutics (Nasdaq: PTGX) has received FDA's Breakthrough Therapy Designation for rusfertide, aimed at treating polycythemia vera (PV) by reducing erythrocytosis. This designation, granted on June 3, 2021, accelerates development for serious conditions and is based on promising Phase 2 trial data showing significant patient improvements. Rusfertide is positioned as the first non-cytoreductive therapy for PV. Protagonist plans to expedite clinical studies, and updated data will be presented at the European Hematology Association meeting from June 9-17, 2021.
Protagonist Therapeutics (PTGX) announced the dosing of the first human subject in a Phase 1 study for PN-232, an oral interleukin-23 receptor antagonist peptide. This trial aims to assess safety, tolerability, and pharmacokinetics. The study consists of three parts: single ascending doses, multiple ascending doses, and food effect evaluations. Protagonist is collaborating with Janssen Biotech, which will handle development past Phase 2. The company may receive milestone payments and has options for product co-detailing in the U.S.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
